11,455 followers
Article: Policymaking for Orphan Drugs and Its Challenges Author: Taeho Greg Rhee, AM Issue: The Bottom Line: Profit Motive in American Medicine Read the article and full issue for free at our site: https://t.co/EEflZoRZQv
3,280 followers
11,455 followers
Before the advent of the Orphan Drug Act of 1983, biotechnology and pharmaceutical companies did not invest in developing drugs and biologics for rare diseases because there was no reasonable expectation that the sales of the drugs would recover the costs.
1,665 followers
RT @JournalofEthics: "To improve the accessibility of orphan drugs for patients with rare diseases, relevant policies should be altered in…